Cytokeratin 14 inhibitors belong to a specific chemical class of compounds designed to target and inhibit the activity of the Cytokeratin 14 (CK14) protein. CK14 is a type I intermediate filament protein and a member of the cytokeratin family, which are structural proteins found in epithelial cells. CK14 is particularly abundant in stratified epithelia, including the skin, oral mucosa, and hair follicles. It plays a crucial role in providing structural support and mechanical integrity to these tissues. CK14 is also considered a marker for specific cell types, such as basal keratinocytes in the skin.
Cytokeratin 14 inhibitors work by specifically targeting the CK14 protein, interfering with its role in maintaining the cytoskeleton and cell structure in stratified epithelial tissues. By doing so, these inhibitors may modulate cellular processes that depend on CK14, impacting tissue development and maintenance. Research into CK14 and its inhibitors is ongoing to unravel their precise mechanisms of action and explore their implications in cellular physiology and tissue function. The study of cytokeratin 14 inhibitors represents an intriguing area of research, contributing to a deeper understanding of the intricate mechanisms governing tissue architecture and cellular organization in different epithelial tissues.
SEE ALSO...
Items 11 to 12 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Quinacrine, Dihydrochloride | 69-05-6 | sc-204222 sc-204222B sc-204222A sc-204222C sc-204222D | 100 mg 1 g 5 g 200 g 300 g | $45.00 $56.00 $85.00 $3193.00 $4726.00 | 4 | |
Quinacrine inhibits autophagy, impacting Cytokeratin 14 degradation and cellular homeostasis. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective p38 MAPK inhibitor, modulating Cytokeratin 14 phosphorylation and related stress response pathways. |